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Abstract
Background: The aim of the present study was to assess the relation between metabolic syn-
drome (MS) and coronary artery disease (CAD) complexity, assessed by Syntax score (SS), 
and severity in non-diabetic patients with stable CAD who underwent coronary angiography, 
and to evaluate whether the MS defined by different definitions, including International Dia-
betes Federation (IDF) and American Heart Association/National Heart Lung Blood Institute  
(AHA/NHLBI) guidelines, similarly correlated with SS.
Methods: The present study is cross sectional and observational with prospective inclusion of 
248 consecutive patients (157 male) who underwent coronary angiography due to stable CAD.
Results: The prevalence of MS was 54.4% according to IDF definition and 50.4% according to 
AHA/NHLBI definition. MS score according to IDF definitions (r = 0.446, p < 0.001), MS sco-
re according to AHA/NHLBI definitions (r = 0.341, p < 0.001) were moderately correlated with 
SS. In Fisher r to z transformation test the correlations of the presence of MS according to IDF 
and AHA/NHLBI definitions with SS were not statistically significant (p = 0.168, z = –1.38).  
The systolic blood pressure (p < 0.001, B = 0.354, 95% CI = –0.308 to 0.228), diastolic blood 
pressure (p = 0.006, B = –0.194, 95% CI = –0.333 to –0.056), age (p = 0.014, B = 0.147, 
95% CI = 0.029 to 0.264), left ventricular ejection fraction (p = 0.031, B = –0.150, 95% CI 
= –0.286 to –0.014), waist/hip circumference (p < 0.001, B = 45.713, 95% CI = 23.235 to 
68.1919) and log10 high density lipoprotein (p < 0.001, B = –22.209, 95% CI = –33.298 to 
–11.119) were the independent predictors of SS in linear regression analysis.
Conclusions: MS is associated with the presence and complexity of CAD. Besides the presence 
of discrepancy in the limits of waist circumference, both IDF and AHA/NHLBI criteria were 
similarly correlated with CAD complexity. (Cardiol J 2014; 21, 3: 245–251)
Key words: metabolic syndrome, Syntax score, coronary, cardiovascular,  
IDF, AHA/NHLBI
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Introduction
The metabolic syndrome (MS) is characterized 
by visceral adiposity, insulin resistance, dyslipidemia 
and increased blood pressure [1, 2]. The American 
Heart Association/National Heart Lung Blood In-
stitute (AHA/NHLBI) and International Diabetes 
Federation (IDF) criteria are widely used for defi-
ning MS. Patients with MS are at increased risk of 
cardiovascular events (2-fold increase in cardiova-
scular outcomes, cardiovascular mortality, myocar-
dial infarction and stroke, and a 1.5-fold increase in 
all-cause mortality) [3, 4]. However, there is still 
a controversy about the association of MS with 
stable coronary artery disease (CAD) [5–10].
The Syntax score (SS) is a widely accepted 
CAD complexity score based on lesion morphology. 
The SS was correlated with cardiovascular morta-
lity and morbidity [11]. Higher SS was correlated 
with poor outcome and major adverse cardiovascu-
lar and cerebrovascular events (MACCE) in many 
studies [11–14]. Recently it has been reported that 
atherosclerotic plaque compositions of patients 
with MS who did not have diabetes mellitus had 
similar features as patients with diabetes [15, 16]. 
The CAD complexity is not adequately evaluated 
in patients with MS. The aim of the present study 
was to assess the relationship between MS and 
CAD complexity and severity in non-diabetic pa-
tients with stable CAD who underwent coronary 
angiography (CAG) and to evaluate whether the 
MS defined by different definitions, including IDF 
and AHA/NHLBI guidelines, similarly correlated 
with SS.
Methods
The present study is cross sectional and ob-
servational with prospective inclusion of 248 con-
secutive patients (157 male) who underwent CAG 
due to stable CAD (stable angina and/or ischemia) 
between May 2012 and February 2013. Informed 
consent was obtained from all the subjects, and the 
investigation conforms to the principles outlined 
in the Declaration of Helsinki. The study protocol 
was approved by the ethics committee.
Patients with acute coronary syndrome (ACS) 
and previous myocardial infarction, history of 
myocardial revascularization procedure, conge-
nital heart disease, dilated or constrictive cardio-
myopathy, diabetes mellitus, peripheral arterial 
disease, moderate to severe valvular heart disease, 
cerebrovascular disease, congestive heart failure 
(left ventricular ejection fraction [LVEF] £ 40%), 
renal failure (estimated creatinine clearance 
< 60 mL/min/1.73 m2) and cancer were excluded 
from the study.
The MS was defined by the most recent de-
finition from AHA/NHLBI and IDF consisting of 
≥ 3 of the following criteria: fasting glucose 
≥ 100 mg/dL or antidiabetic treatment; blood 
pressure ≥ 130/85 mm Hg or antihypertensive 
medication; triglycerides ≥ 150 mg/dL or specific 
treatment for this lipid abnormality; high density 
lipoprotein cholesterol (HDL-C) < 50 mg/dL in wo-
men and < 40 mg/dL in men or specific treatment 
for this lipid abnormality; waist circumference 
(WC) ≥ 88 cm in women for AHA/NHLBI and 
≥ 80 for IDF and ≥ 102 cm in men for AHA/NHLBI 
and ≥ 94 for IDF [1, 2].
Weights of the patients, in light clothes and 
without shoes, were measured in kilograms, and 
their heights were also measured. Body mass index 
(BMI) was calculated by dividing body weight in 
kilograms by the square of body height in meters. 
WC was measured between the last rib and iliac 
crest on the midline while the patient was standing. 
Hip circumference (HC) was measured by using 
the line between the right and left great trochanter 
of the femur. Transthoracic echocardiographic as-
sessment (Vivid S5 General Electric, Norway) was 
performed in patients according to the standards 
of the American Society of Echocardiography. Left 
ventricular mass (LVM) was calculated according 
to Devereux formula:
LVM: 0.8 × 1.04 ×  
× [(LVEDD + IVS + PW)3 – LVEDD3] + 0.6
LVM index (LVMI): LVM/body surface area.
Blood pressure was measured, in compliance 
with World Health Organization guidelines, by using 
a mercury sphygmomanometer (ERKA, Germany) 
with a cuff appropriate to the arm circumference, 
in patients at rest for 20 min (Korotkoff phase I for 
systolic blood pressure [SBP] and V for diastolic 
blood pressure [DBP]) at least 3 times and the 
average of the measurements was calculated. Hy-
pertension was defined by a previous diagnosis of 
hypertension or the presence of SBP ≥ 140 mm Hg 
or DBP ≥ 90 mm Hg (mean of 2 consecutive 
measurements). Diabetes was defines as fasting 
plasma glucose ≥ 126 mg/dL or plasma glucose 
level ≥ 200 mg/dL 2 h after the 75 mg oral gluco-
se tolerance test or symptoms of hyperglycemia 
accompanied by casual plasma glucose ≥ 200 mg/dL 
or HbA1c ≥ 6.5% or patients using antidiabetic 
medications.
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Pulse pressure = SBP – DBP
Mean blood pressure = SBP + 2 × DBP/3
All cases underwent diagnostic coronary 
angiography according to Judkins technique. The 
left main, left anterior descending, circumflex, and 
right coronary arteries were defined as major coro-
nary vessels. Patients with slow flow in the absence 
of any discernible lesions were also excluded from 
the study. Each coronary lesion producing ≥ 50% 
luminal obstruction in vessels with a diameter 
≥ 1.5 mm was separately scored and added to pro-
vide the vessel SS, and then summed to provide 
the overall patient SS (www.Syntaxscore.com). 
The SS was calculated using dedicated software 
(version 2.11) that integrates the number of le-
sions with their specific weighting factors based 
on the amount of myocardium distal to the lesion 
and the morphologic features of each single lesion. 
Obstructive CAD was defined as stenosis of 50% 
or more in any coronary vessel. Coronary arteries 
without luminal irregularity on CAG were accepted 
normal coronary arteries.
Patients who self-reported as having smoked 
during the previous 6 months were classified as 
smokers. Venous blood samples were drawn after 
a 12-h overnight fast. Serum glucose, total cho-
lesterol and triglycerides were determined using 
standard automatic enzymatic methods. HDL-C 
was determined after specific precipitation and 
low density lipoprotein cholesterol (LDL-C) was 
determined by the Friedewald formula.
Statistical analysis
Analyses were conducted using SPSS 17.0 
(SPSS for Windows 17.0, Chicago, Illinois). 
Continuous variables were expressed as mean 
± standard deviation (for parameters with normal 
distribution), median (interquartile range, IQR) (for 
parameters with none normal distribution) and ca-
tegorical variables were expressed as percentages. 
Comparison of categorical variables between the 
groups was performed using the c2 test. Analysis 
of normality was performed with the Kolmogorov-
Smirnov test. Comparisons of continuous variables 
between the two groups were performed using the 
independent samples t-test or Mann-Whitney U 
test, as appropriate. Pearson and Spearman cor-
relation analyses were used to analyze correlates 
of SS. To compare the correlation coefficients of 
the presence of MS according to IDF and AHA/ 
/NHLBI definitions with SS, Fisher r to z trans-
formation was performed. Multivariate regression 
analysis was performed to find the independent 
predictors of SS. The logarithmic transformation 
was performed to none normally distributed va-
riables including HDL, fasting glucose and trigly-
ceride levels. The WC, SBP, DBP, sex, age, BMI, 
creatinine, hypertension, hyperlipidemia, LVEF, 
WC/HC ratio, log10 fasting blood glucose, log10 
triglyceride, log10 HDL values were entered to 
linear regression analysis. A 2-sided p < 0.05 
was considered significant within 95% confidence 
interval (CI).
Results
A total of 248 patients, 63.3% male were 
included in the study, with a mean age of 60.95 ± 
± 9.42 (range: 36–83) years. Baseline patients’ 
characteristics are shown in Table 1. Significant 
CAD was present in 133 (53.6%) patients, but sig-
nificantly more common among men (71.48% vs. 
28.6%, p = 0.004). The SS was also significantly 
higher in men: 10.03 ± 11.10 vs. 5.62 ± 8.62, p = 
= 0.001. Patients with significant CAD were older 
and more commonly male. Hypertension and hy-
perlipidemia were common among patients with 
significant CAD. Patients with significant CAD had 
higher BMI, waist circumference, WC/HC ratio, 
fasting blood glucose, pulse and mean arterial 
pressure. MS was common among patients with 
significant CAD.
The prevalence of MS was 54.4% according 
to IDF definitions and 50.4% according to AHA/ 
/NHLBI definition. Patients’ characteristics accor-
ding to IDF and AHA/NHLBI definitions are shown 
in Table 2.
The SS was weakly correlated with age, sex, 
hypertension, BMI, creatinine, mean arterial pres-
sure and LVEF in correlation analysis. The WC 
(r = 0.299, p < 0.001), WC/HC ratio (r = 0.413, 
p < 0.001), HDL (r = –0.283, p < 0.001), pulse 
pressure (r = 0.334, p = 0.001), MS score according 
to IDF definitions (r = 0.360, p < 0.001), MS score 
according to AHA/NHLBI definitions (r = 0.361, 
p < 0.001), presence of MS score according to 
IDF definitions (r = 0.446, p < 0.001), MS score 
according to AHA/NHLBI definitions (r = 0.341, 
p < 0.001) were moderately correlated with SS 
(Table 3). In Fisher r to z transformation test the 
correlations of the presence of MS according to 
IDF and AHA/NHLBI definitions with SS was not 
statistically significant (p = 0.168, z = –1.38).
The  SBP (p < 0.001, B = 0.354, 95% CI = –0.308 
to 0.228), DBP (p = 0.006, B = –0.194, 95% 
CI = –0.333 to –0.056), age (p = 0.014, B = 0.147, 
95% CI = 0.029 to 0.264), LVEF (p = 0.031, 
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B = –0.150, 95% CI = –0.286 to –0.014), WC/HC 
(p < 0.001, B = 45.713, 95% CI = 23.235–68.1919) 
and log10 HDL (p < 0.001, B = –22.209, 95% 
CI = –33.298 to –11.119) were the independent 
predictors of SS in linear regression analysis 
(Table 4).
Discussion
There is limited data regarding the association 
between MS and the presence and complexity of 
CAD in non-diabetic patients. To our knowledge 
this is the first study evaluating and comparing the 
association of CAD complexity with MS defined 
by IDF and AHA/NHLBI in diabetic patients who 
underwent coronary angiography due to suspected 
stable CAD. We found that MS is associated with 
the significant angiographic CAD and presence of 
MS according to both AHA/NHLBI and IDF were 
similarly correlated with SS. Furthermore, there 
was no statistical difference for both definitions 
with the correlation of SS. The SBP, DBP, age, 
LVEF, WC/HC and log10 HDL were the indepen-
dent predictors of SS in linear regression analysis.
There are several definitions of MS [1, 2, 17]. 
Of these, the AHA/NHLBI and IDF definitions 
have emerged as the most widely used. Thus we 
used them. The main difference between these 
criteria concerns the measurement of abdominal 
obesity. Because of this discordance, IDF and 
AHA/NHLBI defined a consensus statement and 
they recommended the IDF cut points be used for 
non-Europeans and either the IDF or AHA/NHLBI 
cut points to be used for people of European origin 
until more data are available [18].
The MS was associated with increased cardio-
vascular disease, cardiovascular mortality, and stro-
ke [4]. Patients with clinically manifest CAD have 
a high prevalence of MS. In patients hospitalized 
for ACS, the prevalence ranged between 43% and 
Table 1. Baseline patients’ characteristics.
Variable Significant CAD (n = 133) No CAD (n = 115) P
Age [year] 62.28 ± 9.45 59.41 ± 9.18 0.016
Male 95 (71.4%) 62 (53.9%) 0.004
Hypertension 81 (60.9%) 51 (44.3%) 0.009
Hyperlipidemia 52 (42.9%) 27 (23.5%) 0.001
Smoking 51 (38.3%) 44 (38.3%) 0.989
Body mass index [kg/m2] 28.48 ± 3.46 26.80 ± 4.97 0.003
WC [cm] 93.86 ± 11.15 83.75 ± 15.64 < 0.001
HC [cm] 97.76 ± 7.35 97.11 ± 8.03 0.509
WC/HC ratio 0.96 ± 0.09 0.86 ± 0.11 < 0.001
Triglyceride [mg/dL] 128 (82) 153 (119) 0.011
High density lipoprotein [mg/dL] 39 (12.5) 48 (15) 0.001
Glucose [mg/dL] 102 (18.5) 98 (12) 0.001
Low density lipoprotein [mg/dL] 143.91 ± 42.68 142.60 ± 33.89 0.787
Total cholesterol [mg/dL] 205.84 ± 49.42 211.34 ± 36.09 0.314
Creatinine [mg/dL] 0.86 ± 0.21 0.82 ± 0.19 0.092
eGFR [mL/min/1.73 m2] 102.44 ± 31.12 100.20 ± 35.50 0.597
Systolic blood pressure [mm Hg] 146.08 ± 13.03 137.94 ± 16.23 < 0.001
Diastolic blood pressure [mm Hg] 87.43 ± 9.18 84.80 ± 11.18 0.046
Pulse pressure [mm Hg] 58.65 ± 11.15 53.14 ± 10.97 < 0.001
Mean arterial pressure [mm Hg] 106.98 ± 9.23 102.51 ± 12.01 0.001
MS score IDF 3.29 ± 1.10 2.03 ± 1.35 < 0.001
MS score AHA 3.07 ± 1.09 1.91 ± 1.21 < 0.001
MS IDF 101 (71.9%) 34 (29.6%) < 0.001
MS AHA 92 (69.2%) 33 (28.7%9 < 0.001
Left ventricular ejection fraction [%] 62.24 ± 8.14 63.86 ± 7.99 0.116
Left ventricular mass index [g/m2] 117.47 ± 38.94 116.84 ± 37.95 0.897
CAD — coronary artery disease; WC — waist circumference; HC — hip circumference; eGFR — estimated glomerular filtration rate;  
MS IDF — metabolic syndrome according to International Diabetes Federation definition; MS AHA/NHLBI — metabolic syndrome according  
to American Heart Association/National Heart Lung Blood Institute definition
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51% [19]. Recently, Al-Aqeedi et al. [20] reported 
that in ACS patients without history of diabetes MS 
was frequent (69.4%) and reduced HDL increased 
fasting blood glucose, and triglycerides were the 
most frequent MS components. Although MS is 
frequently associated with diabetes, in the absence 
of diabetes MS resulted in increased cardiovascular 
events and mortality. The diabetes is associated 
with increased coronary artery lesion complexity 
and severity. Moreover, diabetes is generally accep-
ted as the major underlying patholophysiological 
mechanism of MS causing CAD. Therefore, we 
excluded patients with diabetes.
Although MS was shown to predict cardiova-
scular events, whether MS or any of its components 
are independently associated with cardiovascular 
risk is controversial [21, 22]. MS defined according 
to ATP III and IDF criteria failed to predict coro-
nary heart disease in diabetic patients [23, 24]. 
In our study, the primary aim was to evaluate the 
relationship between the presence of MS based on 
AHA/NHLBI and IDF criteria with CAD complexity 
assessed by SS. We also aimed at testing whether 
the AHA/NHLBI or IDF criteria are similarly corre-
lated with SS. We found that SBP, DBP, age, LVEF, 
WC/HC and HDL were the independent predictors 
of CAD complexity; furthermore, AHA/NHLBI and 
IDF criteria were similarly correlated with SS.
In the MESYAS study it was demonstrated 
that MS is related to a substantial increase in the 
risk of developing CAD [25]. MS components 
confer very different intensities of independent 
risk, from the high independent risk of hypertri-
glyceridemia to the almost complete absence of an 
independent effect of overweight (even appearing 
to be protective, which seems contradictory). MS 
is a marker of CAD risk, but not above and beyond 
the risk associated with its individual components. 
Table 2. The patients’ features according to metabolic syndrome (MS) definitions.









Age [year] 60.61 ± 9.66 61.35 ± 9.15 0.544 60.60 ± 9.35 61.30 ± 9.51 0.559
Male 90 (66.7%) 67 (59.3%) 0.230 81 (64.8%) 76 (61.8%) 0.623
Hypertension 87 (64.4%) 45 (39.8%) < 0.001 80 (64.0%) 52 (42.3%) 0.001
Hyperlipidemia 52 (38.5%) 32 (28.3%) 0.091 47 (37.6%) 37 (30.1%) 0.211
Smoking 55 (40.7%) 40 (35.4%) 0.389 50 (40%) 45 (36.6%) 0.580
Body mass index [kg/m2] 29.26 ± 3.49 25.84 ± 4.45 < 0.001 29.36 ± 3.61 26.02 ± 4.31 < 0.001
WC [cm] 95.76 ± 12.11 81.30 ± 12.72 < 0.001 95.94 ± 12.52 82.29 ± 12.70 < 0.001
HC [cm] 99.68 ± 7.41 94.80 ± 7.11 < 0.001 99.84 ± 7.60 95.04 ± 6.96 < 0.001
WC/HC ratio 0.96 ± 0.10 0.86 ± 0.10 < 0.001 0.96 ± 0.11 0.86 ± 0.10 < 0.001
Triglyceride [mg/dL] 188 (126) 111 (43) < 0.001 191 (124) 111 (48) < 0.001
HDL [mg/dL] 39 (12) 50 (14.5) < 0.001 38 (13) 48 (14) < 0.001
Glucose [mg/dL] 104 (18) 94.5 (12.5) < 0.001 105 (19) 95 (13) < 0.001
LDL [mg/dL] 149.03 ± 39.71 136.45 ± 36.65 0.011 149.63 ± 40.17 136.87 ± 36.36 0.009
Total cholesterol [mg/dL] 211.87 ± 40.06 204.23 ± 40.63 0.171 212.83 ± 47.05 203.88 ± 39.80 0.107
Creatinine [mg/dL] 0.84 ± 0.20 0.85 ± 0.21 0.648 0.83 ± 0.20 0.86 ± 0.21 0.421
eGFR, [mL/min/1.73 m2] 108.62 ± 32.26 92.79 ± 32.32 < 0.001 108.86 ± 31.88 93.82 ± 32.87 < 0.001
SBP [mm Hg] 146.24 ± 12.58 137.60 ± 16.57 < 0.001 146.18 ± 12.75 138.36 ± 16.34 < 0.001
DBP [mm Hg] 88.56 ± 10.32 83.39 ± 9.39 < 0.001 88.31 ± 10.60 84.07 ± 9.39 0.001
Pulse pressure [mm Hg] 57.67 ± 11.64 54.20 ± 10.82 0.016 57.87 ± 11.83 54.28 ± 10.66 0.013
MAP [mm Hg] 107.79 ± 9.68 101.47 ± 11.14 < 0.001 107.60 ± 9.90 102.17 ± 11.07 < 0.001
MS score 3.79 ± 0.76 1.42 ± 0.64 < 0.001 3.61 ± 0.73 1.44 ± 0.63 < 0.001
LVEF [%] 63.48 ± 8.80 62.41 ± 7.18 0.299 64.06 ± 7.64 61.90 ± 8.43 0.035
LVMI [g/m2] 117.76 ± 36.19 116.48 ± 41.05 0.794 117.68 ± 36.26 116.66± 40.62 0.836
Syntax score 10.50 (20.5) 0 (3) < 0.001 10 (20.25) 0 (5) < 0.001
MS IDF — metabolic syndrome according to International Diabetes Federation definition; MS AHA/NHLBI — metabolic syndrome according to 
American Heart Association/National Heart Lung Blood Institute definition; WC — waist circumference; HC — hip circumference; HDL — high 
density lipoprotein; LDL — low density lipoprotein; eGFR — estimated glomerular filtration rate; SBP — systolic blood pressure; DBP — dia-
stolic blood pressure; MAP — mean arterial pressure; LVEF — left ventricular ejection fraction; LVMI — left ventricular mass index
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It was reported that among the components of MS, 
abdominal obesity and low serum HDL-C were sig-
nificant independent predictors for culprit coronary 
plaque rupture [26]. Ertek et al. [5] reported that 
diabetic patients had significantly higher Gensini 
scores among patients with MS. In this study we 
excluded patients with diabetes and found that 
patients with MS had significantly higher CAD 
complexity than those without implicating more 
bifurcation lesions, calcifications, tortuosity, ex-
tensive and diffuse involvement. These findings 
were compatible with the findings of Zheng et al. 
[16] and Marso et al. [15]. Zheng et al. [16] demon-
strated that diabetic and MS patients, compared 
to patients without diabetes mellitus or MS, had 
a larger plaque-plus-media burden, larger amount 
of necrotic core and more frequent virtual histology 
intravascular ultrasound derived thin-cap fibroat-
heroma in coronary arterial trees, implying greater 
plaque vulnerability in diabetes mellitus and MS 
patients. Marso et al. [15] showed that patients 
with diabetes and MS had higher 3-year MACE 
rates and lesion length, plaque burden, necrotic 
core, and calcium content were significantly greater 
among nonculprit lesions of patients with diabetes 
and MS that presented with ACS.
Limitations of the study
The sample size is relatively small. The plas-
ma insulin levels and insulin resistance was not 
studied. This was an angiographic study and as 
such, coronary plaque morphology was not directly 
Table 4. The independent predictors of Syntax score.
Variable p B 95% confidence interval
Waist circumference 0.770 –0.40 –0.308 to 0.228
Systolic blood pressure < 0.001 0.354 0.224 to 0.484
Diastolic blood pressure 0.006 –0.194 –0.333 to –0.056
Sex 0.428 –1.189 –4.185 to 1.758
Age 0.014 0.147 0.029 to 0.264
Body mass index 0.157 –0.434 –1.038 to 0.169
Creatinine 0.819 0.667 –5.073 to 6.407
Hypertension 0.248 –2.715 –6.403 to 0.972
Hyperlipidemia 0.345 1.114 –1.237 to 3.526
Left ventricular ejection fraction 0.031 –0.150 –0.286 to –0.014
Waist circumference/Hip circumference < 0.001 45.713 23.235 to 68.191
Log10 glucose 0.071 18.790 –1.589 to 39.170
Log10 triglyceride 0.157 –3.767 –8.990 to 1.456
Log10 high density lipoprotein < 0.001 –22.209 –33.298 to –11.119







Body mass index 0.128 0.045
Waist circumference 0.299 < 0.001
Hip circumference –0.13 0.835
Waist/Hip circumference ratio 0.413 < 0.001
Triglyceride 0.071 0.265
High density lipoprotein –0.283 < 0.001
Glucose 0.177 0.005
Low density lipoprotein 0.006 0.230
Total cholesterol –0.066 0.299
Creatinine 0.141 0.026
Estimated glomerular filtration rate –0.023 0.719
Systolic blood pressure 0.330 < 0.001
Diastolic blood pressure 0.116 0.069
Pulse pressure 0.334 0.001
Mean arterial pressure 0.227 < 0.001
MS score IDF 0.360 < 0.001
MS score AHA/NHLBI 0.361 < 0.001
MS IDF 0.446 < 0.001
MS AHA/NHLBI 0.341 < 0.001
Left ventricular ejection fraction –0.163 0.010
Left ventricle mass index 0.108 0.091
MS IDF — metabolic syndrome according to International Diabe-
tes Federation definition; MS AHA/NHLBI — metabolic syndrome 
according to American Heart Association/National Heart Lung 
Blood Institute definition
www.cardiologyjournal.org 251
Ahmet Çağrı Aykan et al., Metabolic syndrome, Syntax score
assessed. With quantitative coronary angiography 
analysis we could only measure reference diameter 
and percentage diameter stenosis. However, it 
has been reported that this measurement can be 
misleading, because patients with similar measure-
ments on angiography might have different vessel 
and plaque volume when assessed by intravascular 
ultrasound which enables cross-sectional imaging 
of coronary arteries and provides more comprehen-
sive assessment of atherosclerotic plaque.
Conclusions
MS is associated with the presence and com-
plexity of CAD. Besides the presence of discre-
pancy about the limits of WC, both IDF and AHA/ 
/NHLBI criteria were similarly correlated with CAD 
complexity. This finding suggested that both IDF 
and AHA/NHLBI definitions may be used to eva-
luate and manage for patients at high risk for CAD.
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